In just over a week, I'll be joining Breaking Convention again. It's the most fun conference in the space, and I'm looking forward to seeing you all there. Get a 10% discount with code BLOSSOM10
I'm eager to hear your thoughts, reactions, and especially your ideas on how we can collaborate to overcome these barriers together.
Let's talk. And let's transform possibilities into realities.
Access the report here: psychedelicsandreimbursement.com
This isn't just about research—it's personal. I believe passionately that psychedelic therapies can revolutionise mental healthcare. And as an industry, we have an obligation to ensure that innovation isn't just possible but accessible and affordable.
• Engage early and openly with payers and policymakers.
• Adopt innovative pricing models that align treatment costs with actual patient outcomes.
• Invest in real-world evidence and pilot programs to demonstrate lasting impact.
The path isn't simple, but the potential is enormous.
From navigating intricate country-specific reimbursement hurdles to confronting historical stigma, we've mapped the landscape—and the roadblocks.
But it's not all barriers and challenges. Our report also illuminates clear pathways forward:
This question kept Martin Gisby and me up at night. After months of diving into Europe's complex healthcare systems, we've unpacked the challenges standing between patients and these transformative treatments.
We all know the incredible promise psychedelics hold for conditions like depression, PTSD, and addiction. But what happens after regulatory approval? How do these groundbreaking therapies actually reach the people who need them most?
I'm excited—and frankly, a little nervous—to share something we've been working on for the last 6 months: our new report on reimbursement pathways for psychedelic therapies in Europe supported by Norrsken Mind.
Access the report here: psychedelicsandreimbursement.com
This systematic review (s=45) on psychedelic-assisted psychotherapy for mental disorders finds that psychological interventions are reported with low completeness and high heterogeneity. It also finds that MDMA studies are more homogeneous, with greater procedural detail.
https://blossomanalysis.co…
In November, 115 new psychedelic research articles were published.
In the monthly recap for Blossom, we group and highlight 19 studies that have moved the field forward.
From challenging experiences to the health economics of MDMA 👇
blossomanalysis.com/psychedelic-...
Todoist still rules for personal things (e.g. tire pressure every 2 months)
Then it would be good to have clarity around what that protocol is right? "Sunlight is said to be the best of disinfectants" and all that
It explains how the treatment combines three MDMA-facilitated sessions with non-drug psychotherapy sessions, emphasizing the patient's "inner healing intelligence" as the primary change agent and the therapeutic relationship as the core facilitating condition.
blossomanalysis.com/papers/the-c...
This theoretical framework paper analyzes two Phase III trials of MDMA-assisted therapy for PTSD, describing the conceptual underpinnings and therapeutic approach.
Very limited for ketamine (the therapy part) and Esketamine (but also much more limited in scale vs US). Many challenges to reimbursement beyond that (but some positive signals from the Czech Republic and of course Switzerland)
1) Collect and analyze the psychedelic research (and some consulting too)
2) Examining reimbursement of psychedelic therapies in Europe
3) Dune Prophecy just started ^^
Cool cool, just discovering/exploring the app, feel free to add, will see how I can crosspost the research updates
